TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Early and sensitive diagnosis of Maroteaux-Lamy disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in burnout levels post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in perceived stress post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in continuous physiologic data throughout intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coping abilities post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Headache verbal pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Hemoglobin Values in the Range of 11-13 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Hemoglobin Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in traumatic dissociation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic Resuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burke-Fahn-Marsden Scale (BFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bleeding of grade 2 or greater
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction rate of Hamilton Depression Scale (HDRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Differences in 89Zr-DFO-nimotuzumab uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Responder Status Based on CGI-I Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Variation of Number of copies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Plaque Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive complaints
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevention of graft versus host disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Propofol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six Month Relapse-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Absolute and relative changes in PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clavicula shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to First Confirmed Complete Renal Response (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hot Flash Related Daily Interference Scale (HFRDIS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Number of Participants Who Experienced a Reduction in Hot Flashes Per 24 Hours From Baseline to 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Hot Flashes Per Day From Baseline to 8 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Principal diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of neurologic deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inhibition of Platelet Aggregation to 20 μM ADP at 6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of Platelet Aggregation to 20 μM ADP After 14 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parameters of coagulability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 24-hour pH Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of undetected dry IV bags
Endpoint domain: Adverse events/effects
Primary endpoint: Change in questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychiatric symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation of immune suppression without rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 mucosal shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of asymptomatic DVT and symptomatic VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of vaccination histories collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of active sacroiliitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: long-term safety of pazopanib
Endpoint domain: Adverse events/effects
Primary endpoint: Hormones levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Familial accumulation of breast wall deformities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Words Correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Confirmed Occurrence of Influenza A or B
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular events (CV death, MI, Stroke, UCR)
Endpoint domain: Mortality/survival
Primary endpoint: PASI 75 response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGA score of 0 or 1 at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI 75 response at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGA score of 0 or 1 at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial Numeric Rating Scale (NRS) Pain Score Upon Arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients showing an immunologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinically important venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 13CO2 excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful Epidural Reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month postoperative spinal function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Sleep Patterns Assessed by Children's Sleep Habits Questionnaire (CSHQ)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With a Positive Response Using Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bulbocavernosus reflex assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neurological and functional recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 63-day PCR-adjusted parasitological cure of P. vivax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to therapy from Day 1 of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Frequency of Regulatory Cell Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 10 year survivorship
Endpoint domain: Mortality/survival
Primary endpoint: Change in International RLS Study Group Rating Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle strength development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circulating levels of adult stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average intraoperative power spectral density in the frontal alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the score of MMSE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Postoperative Opioid Pain Medication Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Patient Reported Outcome Measures (PROMs)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of nephrocalcinosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Prothrombin Fragments F1+2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients requiring prolonged ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the plasma concentration versus time Curve from the first observed to last (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of secondary fragility fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: paediatric ankle radiography rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of aortic valve stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of clinical and radiological non-progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with advanced HIV disease (CD4 <100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of CrAg-positivity among HIV patients with advanced disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with no new opportunistic infections at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality rate among HIV patients with advanced disease
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With Procedural Success During the First 30 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women with sleep disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: BRCA1 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRCA1 protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propensity of serum for calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Symptomatic Venous Thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Symptomatic Postoperative Fluid Collection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Major Postoperative Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of job strain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pourability of respiratory secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in redox status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With One or More Treatment Emergent Adverse Events (AEs) or Any Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of ZD4054
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Stent Thrombosis (ST)
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity of adoptive transfer of CMV/EBV specific T-cells
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hypokalemia ≤3.5mEq/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic value in the depth of endometrial infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic value of the lymph nodes metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic value of the distant metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Screening behavior for second primary cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CTEPH-SOLUTION score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROTEM parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of IL-8 in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxidative stress in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Violence Victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Dating Violence Victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Sexual Violence Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Dating Violence Perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombolytic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-fatal complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Received COVID-19 Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum-tolerated dose of ARRY-380 with Trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory (BPI) for painful diabetic peripheral neuropathy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Impression of Change score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Barrett's metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: prophylaxis of intrathecal morphine induced pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of congenital anomalies in fetuses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduced tinnitus annoyance measured via Tinnitus Functional Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduced tinnitus annoyance measured via Iowa Tinnitus Primary Function Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduced tinnitus annoyance measured via Tinnitus Handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PTSD Checklist-Civilian Version (PCL-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax for PF-00251802
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-last) for PF-00251802
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for PF-00251802
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep stages
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in HbA1C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urine sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Primary Patency at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically confirmed 7-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically confirmed 30-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically confirmed sustained abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving seroprotection against measles, mumps and rubella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain biodistribution of [11C]AcAc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain biodistribution of [18F]FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unplanned hospital admission for cardiovascular reasons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Fall rate
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge about anxiety in ASD
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time Until Complete Reversal of Neuromuscular Blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relapse Free Survival time
Endpoint domain: Mortality/survival
Primary endpoint: Number of Menses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in fasting and postprandial insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Injury in lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Ki-67 mean levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease progression defined as a NEWS2 score ≥ 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to Intensive/Medium Care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IGRA performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Loss of reduction assessed by X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Capnia values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simulated Driver Safety Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of adverse events of ipilimumab with BMS-986156 and SBRT targeting liver lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events of ipilimumab with BMS-986156 and SBRT targeting lung lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting liver lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events of nivolumab with BMS-986156 and SBRT targeting lung lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With no Symptoms of Cough, Fever or Dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: the number of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: femoral head blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: femoral head metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of PGx testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of latently infected CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change of the time to Peak intensity (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change of the Mean transit time (MTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change of the Peak intensity (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change of the Area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change of the Wall motion score index (WMSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with change in worst grades for hematological and biochemical toxicities according to CTCAE version 4.03
Endpoint domain: Adverse events/effects